Myriam Barthes is the Co-founder & Chief Operating Officer at Journey Clinical, a telehealth platform that empowers licensed mental health professionals to offer psychedelic therapies in their own practice. She has over 10 years of experience as a management consultant in strategy & performance improvement at Ernst & Young and led the Impact team at an artificial intelligence startup in New York. She brings her operational expertise to serve the mission of Journey Clinical to expand affordable and equitable access to psychedelic therapies.

In today’s episode, Myriam describes the impact of ketamine on the mind and the body, and specifically how ketamine-assisted therapy compares to other psychedelic-assisted therapies. She goes on to discuss the importance of therapeutic alliance when approaching ketamine-assisted therapy and who the best candidates are for participating in this treatment.

You can find out more about Journey Clinical and their work at www.journeyclinical.com